Department of Health Surveillance and Bioethics, Section of Legal Medicine, Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.
Department of Life Sciences and Public Health, Università Cattolica del Sacro Cuore, Rome, Italy.
BMJ Open. 2022 May 17;12(5):e057399. doi: 10.1136/bmjopen-2021-057399.
In primary care, almost 75% of outpatient visits by family doctors and general practitioners involve continuation or initiation of drug therapy. Due to the enormous amount of drugs used by outpatients in unmonitored situations, the potential risk of adverse events due to an error in the use or prescription of drugs is much higher than in a hospital setting. Artificial intelligence (AI) application can help healthcare professionals to take charge of patient safety by improving error detection, patient stratification and drug management. The aim is to investigate the impact of AI algorithms on drug management in primary care settings and to compare AI or algorithms with standard clinical practice to define the medication fields where a technological support could lead to better results.
A systematic review and meta-analysis of literature will be conducted querying PubMed, Cochrane and ISI Web of Science from the inception to December 2021. The primary outcome will be the reduction of medication errors obtained by AI application. The search strategy and the study selection will be conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the population, intervention, comparator and outcome framework. Quality of included studies will be appraised adopting the quality assessment tool for observational cohort and cross-sectional studies for non-randomised controlled trials as well as the quality assessment of controlled intervention studies of National Institute of Health for randomised controlled trials.
Formal ethical approval is not required since no human beings are involved. The results will be disseminated widely through peer-reviewed publications.
在基层医疗中,家庭医生和全科医生接诊的近 75%的门诊患者都涉及药物治疗的延续或启动。由于门诊患者在不受监测的情况下使用的药物数量巨大,因此由于药物使用或处方错误而导致不良事件的潜在风险远高于医院环境。人工智能(AI)应用可以通过提高错误检测、患者分层和药物管理来帮助医疗保健专业人员负责患者安全。目的是调查 AI 算法对基层医疗环境中药物管理的影响,并将 AI 或算法与标准临床实践进行比较,以确定在哪些药物管理领域技术支持可以带来更好的结果。
将对从成立到 2021 年 12 月的 PubMed、Cochrane 和 ISI Web of Science 进行文献的系统评价和荟萃分析。主要结果将是通过 AI 应用减少药物错误。搜索策略和研究选择将根据系统评价和荟萃分析的首选报告项目以及人群、干预、比较和结果框架进行。将采用非随机对照试验的观察性队列和横断面研究的质量评估工具以及国立卫生研究院的随机对照试验的对照干预研究的质量评估来评估纳入研究的质量。
由于不涉及人类,因此不需要正式的伦理批准。研究结果将通过同行评审出版物广泛传播。